

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/157652 A8



(51) International Patent Classification:

C07D 231/40 (2006.01) C07D 413/14 (2006.01)
C07D 401/12 (2006.01) C07D 417/12 (2006.01)
C07D 401/14 (2006.01) C07D 417/14 (2006.01)
C07D 403/12 (2006.01) C07D 471/04 (2006.01)
C07D 403/14 (2006.01) C07D 487/04 (2006.01)
C07D 405/12 (2006.01) C07D 513/04 (2006.01)
C07D 405/14 (2006.01) A61K 31/415 (2006.01)
C07D 413/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2020/050653

(22) International Filing Date:

28 January 2020 (28.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/799,455 31 January 2019 (31.01.2019) US
62/959,042 09 January 2020 (09.01.2020) US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street,
New York, NY 10017 (US).

(72) Inventors: **BEHENNA, Douglas Carl**; c/o Pfizer Inc.,
10777 Science Center Drive, San Diego, CA 92121 (US).
FREEMAN-COOK, Kevin Daniel; c/o Pfizer Inc., 10777

Science Center Drive, San Diego, CA 92121 (US). **HOFF-
MAN, Robert Louis**; c/o Pfizer Inc., 10777 Science Center
Drive, San Diego, CA 92121 (US). **NAGATA, Asako**; c/
o Pfizer Inc., 10777 Science Center Drive, San Diego, CA
92121 (US). **NINKOVIC, Sacha**; c/o Pfizer Inc., 10777
Science Center, San Diego, CA 92121 (US). **SUTTON,
Scott Channing**; c/o Pfizer Inc., 10777 Science Center Drive,
San Diego, CA 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., 235
East 42nd Street, MS 235/9/S20, New York, NY 10017
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2





FIG. 1



(57) Abstract: This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R^1 , R^2 and R^3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

[Continued on next page]



UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

10 September 2020 (10.09.2020)

(48) Date of publication of this corrected version:

19 August 2021 (19.08.2021)

(15) Information about Correction:

see Notice of 19 August 2021 (19.08.2021)